pancreatic cancer
-
Actuate Therapeutics Reports Positive Phase 2 Results for Elraglusib in Metastatic Pancreatic Cancer at ASCO 2025: Trial Achieves Primary Endpoint and Shows Doubled 1-Year Survival
Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.
-
Zai Lab and Novocure to Present PANOVA-3 Trial Results for TTFields Therapy in Pancreatic Cancer at 2025 ASCO Annual Meeting
A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.
